December 09, 2025

Rainer Storb, MD, Receives Distinguished Wallace H. Coulter Award at ASH Annual Congress

The American Society of Hematology (ASH) presented the Wallace H. Coulter Award for Lifetime Achievement in Hematology to Rainer Storb, MD, during the Society’s Annual Congress held in Orlando. Dr. St...

The ASCO Post

December 09, 2025

ASH Recognizes Leaders for Support of Patient Care and Research

The American Society of Hematology (ASH) will honor U.S. Senators Susan Collins (R-ME), Patty Murray (D-WA), Shelley Moore Capito (R-WV), and Tammy Baldwin (D-WI), as well as the patient groups Sick C...

The ASCO Post

December 09, 2025

External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer

A machine learning–based survival model, incorporating preoperative CT images and routinely available clinical data, outperformed standard clinical staging systems in predicting recurrence after surge...

The ASCO Post

December 08, 2025

Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With Acute Myeloid Leukemia

“Pretreatment geriatric assessment in older adults with acute myeloid leukemia is feasible, can identify several functional impairments, and [can] guide the selection of treatment intensity,” resultin...

The ASCO Post

December 07, 2025

Dana-Farber Cancer Institute drives deep remissions in Waldenstrom’s with targeted, time limited therapies

Early phase results from Dana Farber suggest chemo free, time limited strategies may reduce the need for lifelong treatment in Waldenström’s

Dana-Farber

December 05, 2025

Project DISARM: New Cancer Mission Emphasizes Risk Assessment and Early Detection of Ovarian Cancer

Often referred to as a “silent killer,” ovarian cancer is the most lethal of female cancers. Issues of late detection and poor survival rates continue to persevere, leading to increasing levels of inc...

The ASCO Post

December 05, 2025

Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC

In the phase III HARMONi-6 trial, conducted in China, the bispecific antibody ivonescimab, given with chemotherapy, improved progression-free survival by 4.2 months over the PD-1 inhibitor tislelizuma...

The ASCO Post

December 05, 2025

Long-Term Survival With Stereotactic Ablative Radiotherapy vs Surgery for Early-Stage NSCLC

With 10 years of follow-up, no significant difference in survival rates was reported between patients who were treated with stereotactic ablative radiotherapy (SABR) or video-assisted thoracoscopic su...

The ASCO Post

December 05, 2025

LuPSMA-617 Plus Hormone Therapy Improves Radiographic Progression–Free Survival in Metastatic Hormone-Naive Prostate Cancer

The addition of lutetium-177–labeled PSMA-617 (vipivotide tetraxetan; LuPSMA-617), a targeted radionuclide therapy, to standard-of-care androgen-deprivation therapy and an androgen receptor pathway in...

The ASCO Post